BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2021:S1473-3099(21)00485-0. [PMID: 34534511 DOI: 10.1016/S1473-3099(21)00485-0] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Giesen N, Busch E, Schalk E, Beutel G, Rüthrich MM, Hentrich M, Hertenstein B, Hirsch HH, Karthaus M, Khodamoradi Y, Koehler P, Krüger W, Koldehoff M, Krause R, Mellinghoff SC, Penack O, Sandherr M, Seggewiss-Bernhardt R, Spiekermann K, Sprute R, Stemler J, Weissinger F, Wörmann B, Wolf HH, Cornely OA, Rieger CT, von Lilienfeld-Toal M. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. Eur J Cancer 2022;181:102-18. [PMID: 36652889 DOI: 10.1016/j.ejca.2022.11.030] [Reference Citation Analysis]
2 Standing JF, Agyeman AA. Learning and confirming in publicly funded antiviral trials. Lancet Infect Dis 2023;23:132-3. [PMID: 36272434 DOI: 10.1016/S1473-3099(22)00665-X] [Reference Citation Analysis]
3 Martin AK, Feinman JW, Bhatt HV, Fritz AV, Subramani S, Malhotra AK, Townsley MM, Sharma A, Patel SJ, Ha B, Gui JL, Zaky A, Labe S, Teixeira MT, Morozowich ST, Weiner MM, Ramakrishna H. The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. J Cardiothorac Vasc Anesth 2023;37:201-13. [PMID: 36437141 DOI: 10.1053/j.jvca.2022.11.002] [Reference Citation Analysis]
4 Blaskovich MAT, Verderosa AD. Use of Antiviral Agents and other Therapies for COVID-19. Semin Respir Crit Care Med 2023;44:118-29. [PMID: 36646090 DOI: 10.1055/s-0042-1758837] [Reference Citation Analysis]
5 Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1125246] [Reference Citation Analysis]
6 Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 2023;1:CD014962. [PMID: 36695483 DOI: 10.1002/14651858.CD014962.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Delfraissy JF. [French research organization on emerging infectious diseases: from REACTing to ANRS Emerging Infectious Diseases]. Bull Acad Natl Med 2023. [PMID: 36691475 DOI: 10.1016/j.banm.2022.11.017] [Reference Citation Analysis]
8 Temirbulatov II, Kryukov AV, Mirzaev KB, Denisenko NP, Abdullaev SP, Kachanova AA, Sozaeva ZA, Zhiryakova AS, Shevchuk YV, Vechorko VI, Averkov OV, Sychev DA. Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19. Medicinskij sovet 2023. [DOI: 10.21518/2079-701x-2022-16-23-304-309] [Reference Citation Analysis]
9 Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva J, Reuter J, Püntmann I, Patrick-brown TDJH, Westerheim E, Nezvalova-henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard J, Dalgard O, Simensen VC, Baldé A, de Gastines L, del Álamo M, Aydin B, Lund-johansen F, Trabaud M, Diallo A, Halvorsen B, Røttingen J, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D, Dyrhol-riise AM, Stiksrud B, Jenum S, Macpherson ME, Aarskog NR, Røstad K, Skeie LG, Dahl Å, Steen JK, Nur S, Segers F, Korsan KA, Sethupathy A, Sandstå AJ, Paulsen G, Ueland T, Michelsen A, Aukrust P, Berdal JE, Melkeraaen I, Tollefsen MM, Andreassen J, Dokken J, Müller KE, Woll BM, Opsand H, Bogen M, Rød L, Steinsvik T, Åsheim-hansen B, Bjerkreim RH, Berg Å, Moen S, Kvalheim S, Strand K, Gravrok B, Skogen V, Lorentzen EM, Schive SW, Rossvoll L, Hoel H, Engebråten S, Martinsson MS, Thallinger M, Ådnanes E, Hannula R, Bremnes N, Liyanarachi K, Ehrnström B, Kvalshaug M, Berge K, Bygdås M, Gustafsson L, Aballib S, Strand M, Andersen B, Aukrust P, Barratt-due A, Henriksen KN, Kåsine T, Dyrhol-riise AM, Berdal JE, Favory R, Nseir S, Preau S, Jourdain M, Ledoux G, Durand A, Houard M, Moreau A, Rouzé A, Tortuyaux R, Degouy G, Levy C, Liu V, Dognon N, Mariller L, Delcourte C, Reguig Z, Cerf A, Cuvelliez M, Kipnis E, Boyer-beysserre M, Bignon A, Parmentier L, Meddour D, Frade S, Timsit J, Peiffer-smadja N, Wicky P, De Montmollin E, Bouadma L, Dessajan J, Sonneville R, Patrier J, Presente S, Sylia Z, Rioux C, Thy M, Collias L, Bouaraba Y, Dobremel N, Dureau A, Oudeville P, Pointurier V, Rabouel Y, Stiel L, Alzina C, Ramstein C, Ait-oufella H, Hamoudi F, Urbina T, Zerbib Y, Maizel J, Wilpotte C, Piroth L, Blot M, Sixt T, Moretto F, Charles C, Gohier S, Roux D, Le Breton C, Gernez C, Thiry I, Baboi L, Malvy D, Boyer A, Perreau P, Armellini M, De Luca G, Di Pietro OSMM, Romanin B, Brogi M, Castelli F, Amadasi S, Barchiesi F, Canovari B, Coppola N, Pisaturo M, Russo A, Occhiello L, Cataldo F, Rillo MM, Queiruga J, Seco E, Stewart S, Borobia AM, Moraga P, Prieto R, García I, Rivera C, Narro JL, Chacón N, de la Rosa S, Macías M, Barrera L, Serna A, Palomo V, Sánchez MIG, Gutiérrez D, Campos AS, Garfia MÁG, Toyos EB, Cabrera JS, Lucena MI, Lapique EL, Englert P, Khalil Z, Jacobs F, Malaise J, Mukangenzi O, Smissaert C, Hildebrand M, Martiny D, Vervacke A, Scarnière A, Yin N, Michel C, Seyler L, Allard S, Van Laethem J, Verschelden G, Meeuwissen A, De Waele A, Van Buggenhout V, Monteyne D, Noppe N, Belkhir L, Yombi JC, De Greef J, Mesland JB, De Ghellinck L, Kin V, D’aoust C, Bouvier A, Dekeister AC, Hawia E, Gaillet A, Deshorme H, Halleux S, Galand V, Roncon-albuquerque R, Santos LL, Vieira CB, Magalhaes R, Ferreira S, Bernardo M, Jackson A, Sadlier C, O’connell S, Blair M, Manning E, Cusack F, Kelly N, Stephenson H, Keane R, Murphy A, Cunnane M, Keane F, O’regan M, de Barra E, Bellone AM, O’regan S, Carey P, Harte J, Coakley P, Heeney A, Ryan D, Curley G, Mcconkey S, Sulaiman I, Costello R, Mcnally C, Foley C, Trainor S, Jacob B, Vengathodi S, Kent B, Bergin C, Townsend L, Kerr C, Panti N, Sanz AG, Benny B, Dea EO, Galvin N, Burke C, Galvin A, Aisiyabi S, Lobo D, Laffey J, Mcnicolas B, Cosgrave D, Sheehan JR, Nita C, Hanley C, Kelly C, Kernan M, Murray J, Staub T, Henin T, Damilot G, Bintener T, Colling J, Ferretti C, Werer C, Stammet P, Braquet P, Arendt V, Calvo E, Michaux C, Mediouni C, Znati A, Montanes G, Garcia L, Thomé C, Breitkopf R, Peer A, Lehner G, Bellman R, Ditlbacher A, Finkenstedt A, Zotter K, Hernandez CP, Rajsic S, Lanthaler B, Greil R, Tamás K, Kovácsné-levang S, Sipos D, Kappéter A, Halda-kiss B, Madarassi-papp E, Hajdu E, Bende B, Konstantinos T, Moschopoulos C, Labrou E, Tsakona M, Grigoropoulos I, Kotanidou A, Fragkou P, Theodorakopoulou M, Pantazi E, Jahai E, Moukouli M, Siafakas D, Mühlbauer B, Dembinski R, Stich K, Schneider G, Nagy A, Grodová K, Kubelová M, Součková L, Švábová HK, Demlová R, Sonderlichová S, Unal S, Inkaya AC, de Bono S, Kartman CE, Adams DH, Crowe B, Yazdanapanah Y, Unal S, Schneider G, Mühlbauer B, Ødegård T, Bakkehøi G, Autran B, Bjørås M, Lambellerie XD, Mezzarri F, Guedj J, Esperou H, Lumbroso J, Welte T, Calmy A, Pischke S, Treweek S, Goetghebeur E, Doussau A, Weiss L, Hulstaert F, Botgros R, del Alamo M, Chung F, Lumbroso J, Zeitlinger M, Escalera BN, Csajka C, Williams C, Amstutz A, Rüegg CS, Burdet C, Massonnaud C, Belhadi D, Mentré F, Aroun M, Mentré F, Ehrmann S, Espoerou H, Burdet C, Falk RS, Bjordal K, Bakkehøi G, Ødegård T, Barratt-due A, EU SolidAct study group. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Crit Care 2023;27:9. [DOI: 10.1186/s13054-022-04205-8] [Reference Citation Analysis]
10 Abdelnabi R, Maes P, de Jonghe S, Weynand B, Neyts J. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. Front Pharmacol 2022;13:1072202. [PMID: 36605401 DOI: 10.3389/fphar.2022.1072202] [Reference Citation Analysis]
11 Fisher JM, Subbian V, Essay P, Pungitore S, Bedrick EJ, Mosier JM. Outcomes in Patients with Acute Hypoxemic Respiratory Failure Secondary to COVID-19 Treated with Noninvasive Respiratory Support versus Invasive Mechanical Ventilation. medRxiv 2022:2022. [PMID: 36597544 DOI: 10.1101/2022.12.19.22283704] [Reference Citation Analysis]
12 Jeon J, Chin B. Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea. J Korean Med Sci 2022;37. [DOI: 10.3346/jkms.2022.37.e352] [Reference Citation Analysis]
13 Alonso-navarro R, Ramírez M, Masiá M, Paredes R, Montejano R, Povar-echeverria M, Carratalà J, Salavert M, Bernal E, Dueñas C, Flores J, Fanjul F, Gutierrez I, Rico V, Mateu L, Cadiñanos J, Berenguer J, Soriano A. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses.. [DOI: 10.21203/rs.3.rs-2273729/v1] [Reference Citation Analysis]
14 Wang Z, Yang L, Song XQ. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol 2022;13:1015355. [PMID: 36561747 DOI: 10.3389/fimmu.2022.1015355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lei S, Chen X, Wu J, Duan X, Men K. Small molecules in the treatment of COVID-19. Signal Transduct Target Ther 2022;7:387. [PMID: 36464706 DOI: 10.1038/s41392-022-01249-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Pagliano P, Sellitto C, Ascione T, Scarpati G, Folliero V, Piazza O, Franci G, Filippelli A, Conti V. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov 2022;17:1299-311. [PMID: 36508255 DOI: 10.1080/17460441.2022.2153828] [Reference Citation Analysis]
17 Casalini G, Giacomelli A, Antinori S. Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. Expert Opin Drug Saf 2022;21:1483-94. [PMID: 36597859 DOI: 10.1080/14740338.2022.2160446] [Reference Citation Analysis]
18 Dioverti V, Boghdadly ZE, Shahid Z, Waghmare A, Abidi MZ, Pergam S, Boeckh M, Dadwal S, Kamboj M, Seo S, Chemaly RF, Papanicolaou GA. Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). Transplant Cell Ther 2022;28:810-21. [PMID: 36103987 DOI: 10.1016/j.jtct.2022.09.002] [Reference Citation Analysis]
19 Li X, Wang W, Yan S, Zhao W, Xiong H, Bao C, Chen J, Yue Y, Su Y, Zhang C. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019487] [Reference Citation Analysis]
20 Zerbit J, Detroit M, Chevret S, Pene F, Luyt C, Ghosn J, Eyvrard F, Martin-blondel G, Sarton B, Clere-jehl R, Moine P, Cransac A, Andreu P, Labruyère M, Albertini L, Huon J, Roge P, Bernard L, Farines-raffoul M, Villiet M, Venet A, Dumont LM, Kaiser J, Chapuis C, Goehringer F, Barbier F, Desjardins S, Benzidi Y, Abbas N, Guerin C, Batista R, Llitjos J, Kroemer M. Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). JCM 2022;11:6545. [DOI: 10.3390/jcm11216545] [Reference Citation Analysis]
21 Luque-paz D, Sesques P, Wallet F, Bachy E, Ader F, Alcazer V, Bachy E, Balsat M, Barraco F, Bouafia-sauvy F, Ducastelle-leprêtre S, Ferrant E, Ghesquières H, Golfier C, Heiblig M, Karlin L, Labussière-wallet H, Lazareth A, Larcher M, Lequeu H, Mareek A, Safar V, Wallet. F. B-cell malignancies and COVID-19: a narrative review. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.10.030] [Reference Citation Analysis]
22 Wang W, Lee Y, Wang Y, Chen J, Lee S, Tsao S. A case series report on successful management of patients with COVID-19-associated lymphopenia and potential application of PG2. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1009557] [Reference Citation Analysis]
23 Tacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein WO, Berg T; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), vertreten durch Frank Tacke, Markus Cornberg, Martina Sterneck, Jonel Trebicka, Thomas Berg, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), vertreten durch Wolf Bechstein. S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Registernummer: 021-031 – Stand 15. Juni 2022. Z Gastroenterol 2022;60:1678-98. [PMID: 36368659 DOI: 10.1055/a-1934-1989] [Reference Citation Analysis]
24 Wagoner J, Herring S, Hsiang TY, Ianevski A, Biering SB, Xu S, Hoffmann M, Pöhlmann S, Gale M Jr, Aittokallio T, Schiffer JT, White JM, Polyak SJ. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiol Spectr 2022;10:e0333122. [PMID: 36190406 DOI: 10.1128/spectrum.03331-22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Castro AD, Mayr FB, Talisa VB, Shaikh OS, Omer SB, Yende S, Butt AA. Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19. JAMA Netw Open 2022;5:e2238507. [DOI: 10.1001/jamanetworkopen.2022.38507] [Reference Citation Analysis]
26 Spagnuolo V, Voarino M, Tonelli M, Galli L, Poli A, Bruzzesi E, Racca S, Clementi N, Oltolini C, Tresoldi M, Rovere Querini P, Dagna L, Zangrillo A, Ciceri F, Clementi M, Castagna A; COVID-BioB Study Group. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. Drug Des Devel Ther 2022;16:3645-54. [PMID: 36268521 DOI: 10.2147/DDDT.S369473] [Reference Citation Analysis]
27 Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O; Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020), the COVID‐19 Task Force. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). Acute Med Surg 2022;9:e789. [PMID: 36267628 DOI: 10.1002/ams2.789] [Reference Citation Analysis]
28 Cheng Q, Zhao G, Chen J, Jia Q, Fang Z. Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. Medicine 2022;101:e30998. [DOI: 10.1097/md.0000000000030998] [Reference Citation Analysis]
29 Pelle MC, Zaffina I, Lucà S, Forte V, Trapanese V, Melina M, Giofrè F, Arturi F. Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. Life (Basel) 2022;12:1605. [PMID: 36295042 DOI: 10.3390/life12101605] [Reference Citation Analysis]
30 Murton M, Drane E, Jarrett J, Cornely OA, Soriano A. Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review. Infection 2022. [PMID: 36224452 DOI: 10.1007/s15010-022-01930-8] [Reference Citation Analysis]
31 Donepudi B, Agarwal S, Thakur L. Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia. Case Rep Crit Care 2022;2022:8807957. [PMID: 36267193 DOI: 10.1155/2022/8807957] [Reference Citation Analysis]
32 Filev R, Rostaing L, Lyubomirova M, Bogov B, Kalinov K, Svinarov D. COVID-19 Infection in Chronic Kidney Disease Patients in Bulgaria: Risk Factors for Death and Acute Kidney Injury. J Pers Med 2022;12. [PMID: 36294815 DOI: 10.3390/jpm12101676] [Reference Citation Analysis]
33 Labarrere CA, Kassab GS. Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease. Front Microbiol 2022;13:979719. [DOI: 10.3389/fmicb.2022.979719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bennett B, Tahir H, Ganguly S, Moorthy A. An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. Expert Opin Pharmacother 2022. [PMID: 36180063 DOI: 10.1080/14656566.2022.2131395] [Reference Citation Analysis]
35 White H, Mcdonald SJ, Barber B, Davis J, Burr L, Nair P, Mukherjee S, Tendal B, Elliott J, Mcgloughlin S, Turner T. Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce. Medical Journal of Australia 2022;217:368-378. [DOI: 10.5694/mja2.51718] [Reference Citation Analysis]
36 Hanafusa M, Nawa N, Goto Y, Kawahara T, Miyamae S, Ueki Y, Nosaka N, Wakabayashi K, Tohda S, Tateishi U, Fujiwara T. Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study. J Med Virol 2023;95:e28168. [PMID: 36148941 DOI: 10.1002/jmv.28168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol 2022;77:1161-97. [PMID: 35868584 DOI: 10.1016/j.jhep.2022.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
38 Neris Almeida Viana S, do Reis Santos Pereira T, de Carvalho Alves J, Tianeze de Castro C, Santana C da Silva L, Henrique Sousa Pinheiro L, Nougalli Roselino M. Benefits of probiotic use on COVID-19: A systematic review and meta-analysis. Crit Rev Food Sci Nutr 2022;:1-13. [PMID: 36178362 DOI: 10.1080/10408398.2022.2128713] [Reference Citation Analysis]
39 Jaroszewicz J, Kowalska J, Pawłowska M, Rogalska M, Zarębska-michaluk D, Rorat M, Lorenc B, Czupryna P, Sikorska K, Piekarska A, Dworzańska A, Zaleska I, Mazur W, Kozielewicz D, Kłos K, Podlasin R, Angielski G, Oczko-grzesik B, Figlerowicz M, Szetela B, Bolewska B, Frańczak-chmura P, Flisiak R, Tomasiewicz K. Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. Cancers 2022;14:4720. [DOI: 10.3390/cancers14194720] [Reference Citation Analysis]
40 Alonso-Navarro R, Cuesta G, Santos M, Cardozo C, Rico V, Garcia-Pouton N, Tuset M, Bodro M, Morata L, Puerta-Alcalde P, Herrera S, Soria D, Aldea M, Mensa J, Martínez JA, Del Rio A, Vila J, Garcia F, Garcia-Vidal C, Marcos MA, Soriano A. Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized Patients With Coronavirus Disease 2019: Impact on the Length of Hospital Stay and Mortality. Clin Infect Dis 2023;76:32-8. [PMID: 36097825 DOI: 10.1093/cid/ciac760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Wu Z, Han Z, Liu B, Shen N. Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. Front Pharmacol 2022;13:971890. [DOI: 10.3389/fphar.2022.971890] [Reference Citation Analysis]
42 Peng L, Gao L, Wu X, Fan Y, Liu M, Chen J, Song J, Kong J, Dong Y, Li B, Liu A, Bao F. Lung Organoids as Model to Study SARS-CoV-2 Infection. Cells 2022;11:2758. [PMID: 36078166 DOI: 10.3390/cells11172758] [Reference Citation Analysis]
43 Aksak-Wąs BJ, Chober D, Serwin K, Scheibe K, Niścigorska-Olsen J, Niedźwiedź A, Dobrowolska M, Żybul K, Kubacka M, Zimoń A, Hołda E, Mieżyńska-Kurtycz J, Gryczman M, Jamro G, Szakoła P, Parczewski M. Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19. J Inflamm Res 2022;15:4907-20. [PMID: 36046662 DOI: 10.2147/JIR.S378347] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Mehta M, Navarra A, Mogal R. A practical update on the management of patients with COVID-19. Clin Med (Lond) 2022;22:468-74. [PMID: 36507813 DOI: 10.7861/clinmed.2022-0080] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Packham A, Spence N, Goodman A. Evolving role of novel COVID-19 Medicine Delivery Units. Integ Health J 2022;4:e000135. [DOI: 10.1136/ihj-2022-000135] [Reference Citation Analysis]
46 Polivka L, Gajdacsi J, Fazekas L, Sebok S, Barczi E, Hidvegi E, Sutto Z, Dinya E, Maurovich-Horvat P, Szabo AJ, Merkely B, Müller V. Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment. J Glob Health 2022;12:05031. [PMID: 36040909 DOI: 10.7189/jogh.12.05031] [Reference Citation Analysis]
47 Terkes V, Lisica K, Marusic M, Verunica N, Tolic A, Morovic M. Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study. JCM 2022;11:5066. [DOI: 10.3390/jcm11175066] [Reference Citation Analysis]
48 Wang S, Gelfand JM, Calabrese C. Outpatient Management of COVID-19: A Primer for the Dermatologist. Curr Derm Rep. [DOI: 10.1007/s13671-022-00368-3] [Reference Citation Analysis]
49 Ouyang J, Zaongo SD, Harypursat V, Li X, Routy JP, Chen Y. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. Front Public Health 2022;10:945448. [PMID: 36003629 DOI: 10.3389/fpubh.2022.945448] [Reference Citation Analysis]
50 Boast A, Curtis N, Holschier J, Purcell R, Bannister S, Plover C, Chinnapan M, Burgner D, Boyce SL, Mcnab S, Gwee A, on behalf of the RCH COVID-19 Treatment Working Group. An Approach to the Treatment of Children With COVID-19. Pediatric Infectious Disease Journal 2022;41:654-662. [DOI: 10.1097/inf.0000000000003576] [Reference Citation Analysis]
51 Leither LM, Buckel W, Brown SM. Care of the Seriously Ill Patient with SARS CoV-2. Medical Clinics of North America 2022. [DOI: 10.1016/j.mcna.2022.08.002] [Reference Citation Analysis]
52 Avery RK. Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. Transplantation 2022;106:1528-37. [PMID: 35700481 DOI: 10.1097/TP.0000000000004200] [Reference Citation Analysis]
53 Murphy SL, Halvorsen B, Barratt-Due A, Am DR, Aukrust P, Trøseid M, Dahl TB. Remdesivir modifies interferon response in hospitalized COVID-19 patients. J Infect 2022:S0163-4453(22)00450-9. [PMID: 35914611 DOI: 10.1016/j.jinf.2022.07.021] [Reference Citation Analysis]
54 Tempestilli M, Ascoli Bartoli T, Benvenuto D, Stazi GV, Marchioni L, Nicastri E, Agrati C. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects. J Antimicrob Chemother 2022:dkac234. [PMID: 35848782 DOI: 10.1093/jac/dkac234] [Reference Citation Analysis]
55 Faist A, Janowski J, Kumar S, Hinse S, Çalışkan DM, Lange J, Ludwig S, Brunotte L. Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond. Cells 2022;11:2198. [DOI: 10.3390/cells11142198] [Reference Citation Analysis]
56 Czura CJ, Bikson M, Charvet L, Chen JDZ, Franke M, Fudim M, Grigsby E, Hamner S, Huston JM, Khodaparast N, Krames E, Simon BJ, Staats P, Vonck K. Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients. Front Neurol 2022;13:897124. [DOI: 10.3389/fneur.2022.897124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Grégoire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Front Immunol 2022;13:932360. [DOI: 10.3389/fimmu.2022.932360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wong CKH, Au ICH, Cheng WY, Man KKC, Lau KTK, Mak LY, Lui SL, Chung MSH, Xiong X, Lau EHY, Cowling BJ. Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study. Aliment Pharmacol Ther 2022;56:121-30. [PMID: 35318694 DOI: 10.1111/apt.16894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
59 Hites M, Vincent J. Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. Viruses 2022;14:1427. [DOI: 10.3390/v14071427] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ramos-rincon J, López-carmona M, Cobos-palacios L, López-sampalo A, Rubio-rivas M, Martín-escalante M, de-Cossio-Tejido S, Taboada-martínez M, Muiño-miguez A, Areses-manrique M, Martinez-cilleros C, Tuñón-de-almeida C, Abella-vázquez L, Martínez-gonzalez A, Díez-garcía L, Ripper C, Asensi V, Martinez-pascual A, Guisado-vasco P, Lumbreras-bermejo C, Gómez-huelgas R; on behalf of the SEMI-COVID-19 Network. Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. JCM 2022;11:3769. [DOI: 10.3390/jcm11133769] [Reference Citation Analysis]
61 Destache CJ, Ahmad F, Rajendrapasad S, Loranger A, Pruett W, Jagan N, Krajicek B, Schmidt D, Quimby D, Velagapudi M, Boldt D, Hayes S, Anthone J, Kessel B, Vivekanandan R. COVID-19 Mortality and Therapeutics in Nebraska and Southwest Iowa during Early Pandemic. Pharmacy 2022;10:69. [DOI: 10.3390/pharmacy10040069] [Reference Citation Analysis]
62 Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, Rattanasompattikul M, Mahasirimongkol S, Chokephaibulkit K. Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study.. [DOI: 10.1101/2022.06.06.22275902] [Reference Citation Analysis]
63 Leegwater E, Moes DJAR, Bosma LBE, Ottens TH, van der Meer IM, van Nieuwkoop C, Wilms EB. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients. Antimicrob Agents Chemother 2022;:e0025422. [PMID: 35647646 DOI: 10.1128/aac.00254-22] [Reference Citation Analysis]
64 Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentré F, Burdet C; DisCoVeRy Study Group. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infect Dis 2022;22:764-5. [PMID: 35643099 DOI: 10.1016/S1473-3099(22)00295-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Russo P, Tacconelli E, Olimpieri PP, Celant S, Colatrella A, Tomassini L, Palù G. Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses 2022;14:1197. [DOI: 10.3390/v14061197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Lupașcu (Moisi) RE, Ilie MI, Velescu BȘ, Udeanu DI, Sultana C, Ruță S, Arsene AL. COVID-19-Current Therapeutical Approaches and Future Perspectives. Processes 2022;10:1053. [DOI: 10.3390/pr10061053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Светлицкая О, Еремин С, Шаранова О, Кенденков О, Сирош Ю. Efficacy of Remdesivir in the Intensive Care of Patients with COVID-19-associated Acute Respiratory Distress Syndrome. Рецепт 2022. [DOI: 10.34883/pi.2022.25.2.009] [Reference Citation Analysis]
68 . Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)00519-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 38] [Article Influence: 24.0] [Reference Citation Analysis]
69 Drosos AA, Pelechas E, Voulgari PV. Treatment strategies of Covid-19. A rheumatology perspective. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value Health 2022:S1098-3015(22)00158-9. [PMID: 35490085 DOI: 10.1016/j.jval.2022.03.016] [Reference Citation Analysis]
71 Zhu F, Ang JY. COVID-19 Infection in Children: Diagnosis and Management. Curr Infect Dis Rep. [DOI: 10.1007/s11908-022-00779-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
72 Kojima Y, Nakakubo S, Takei N, Kamada K, Yamashita Y, Nakamura J, Matsumoto M, Horii H, Sato K, Shima H, Suzuki M, Konno S. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study. Medicina 2022;58:513. [DOI: 10.3390/medicina58040513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
73 García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, Bouza E. Pharmacological treatment of COVID-19: an opinion paper. Rev Esp Quimioter 2022;35:115-30. [PMID: 34894208 DOI: 10.37201/req/158.2021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
74 Ader F, Bouscambert-duchamp M, Hites M, Peiffer-smadja N, Poissy J, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Fougerou C, Lê M, Peytavin G, Mercier N, Velou P, Tubiana S, Lescure X, Faure E, Nseir S, Richard J, Wallet F, Goehringer F, Lefèvre B, Kimmoun A, Raffi F, Gaborit B, Reignier J, Lanoix J, Andrejak C, Zerbib Y, Bani-sadr F, Mourvilliers B, Danion F, Ruch Y, Clere-jehl R, Le Moing V, Klouche K, Lacombe K, Martin-blondel G, Vardon-bounes F, Cabié A, Turmel J, Piroth L, Blot M, Botelho-nevers É, Gagneux-brunon A, Thiery G, Bénézit F, Gaci R, Mootien J, Gallien S, Garot D, Bouiller K, Epelboin L, Jauréguiberry S, Gaymard A, Verschelden G, Braz S, Ferreira Ribeiro JM, Joannidis M, Staub T, Altdorfer A, Greil R, Egle A, Guedj J, Noret M, Roncon-albuquerque R, Paiva J, Lina B, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial.. [DOI: 10.1101/2022.03.30.22273206] [Reference Citation Analysis]
75 Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 2022. [PMID: 35354968 DOI: 10.1038/s41579-022-00713-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 33.0] [Reference Citation Analysis]
76 Zapata-cardona MI, Flórez-álvarez L, Zapata-builes W, Guerra-sandoval AL, Guerra-almonacid CM, Hincapié-garcía J, Rugeles MT, Hernandez JC. Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 in vitro. Front Microbiol 2022;13:721103. [DOI: 10.3389/fmicb.2022.721103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Ruggeri M, Signorini A, Caravaggio S, Rua J, Luís N, Braz S, Aragão F. Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study. Clin Drug Investig 2022. [PMID: 35298832 DOI: 10.1007/s40261-022-01128-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Obermann W, Friedrich A, Madhugiri R, Klemm P, Mengel JP, Hain T, Pleschka S, Wendel H, Hartmann RK, Schiffmann S, Ziebuhr J, Müller C, Grünweller A. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity. Viruses 2022;14:519. [DOI: 10.3390/v14030519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL; Scientific Medical Policy Committee of the American College of Physicians*. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3). Ann Intern Med 2022. [PMID: 35226518 DOI: 10.7326/M21-4810] [Reference Citation Analysis]
80 Cihlar T, Mackman RL. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antiviral Therapy 2022;27:135965352210827. [DOI: 10.1177/13596535221082773] [Reference Citation Analysis]
81 Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, Cavayas YA, Chagnon N, Cheng MP, Conly J, Costiniuk C, Daley P, Daneman N, Douglas J, Downey C, Duan E, Duceppe E, Durand M, English S, Farjou G, Fera E, Fontela P, Fowler R, Fralick M, Geagea A, Grant J, Harrison LB, Havey T, Hoang H, Kelly LE, Keynan Y, Khwaja K, Klein G, Klein M, Kolan C, Kronfli N, Lamontagne F, Lau R, Fralick M, Lee TC, Lee N, Lim R, Longo S, Lostun A, MacIntyre E, Malhamé I, Mangof K, McGuinty M, Mergler S, Munan MP, Murthy S, O'Neil C, Ovakim D, Papenburg J, Parhar K, Parvathy SN, Patel C, Perez-Patrigeon S, Pinto R, Rajakumaran S, Rishu A, Roba-Oshin M, Rushton M, Saleem M, Salvadori M, Scherr K, Schwartz K, Semret M, Silverman M, Singh A, Sligl W, Smith S, Somayaji R, Tan DHS, Tobin S, Todd M, Tran TV, Tremblay A, Tsang J, Turgeon A, Vakil E, Weatherald J, Yansouni C, Zarychanski R; Canadian Treatments for COVID-19 (CATCO)., Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ 2022;194:E242-51. [PMID: 35045989 DOI: 10.1503/cmaj.211698] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
82 Ader F, Peiffer-smadja N, Poissy J, Bouscambert-duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure F, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-jehl R, Bouiller K, Navellou J, Tolsma V, Cabie A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix J, Makinson A, Martin-blondel G, Bouadma L, Botelho-nevers E, Gagneux-brunon A, Epaulard O, Piroth L, Wallet F, Richard J, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial.. [DOI: 10.1101/2022.02.16.22271064] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Rafia R, Martyn-st James M, Harnan S, Metry A, Hamilton J, Wailoo A. A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales. Value in Health 2022. [DOI: 10.1016/j.jval.2021.12.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med 2022;386:305-15. [PMID: 34937145 DOI: 10.1056/NEJMoa2116846] [Cited by in Crossref: 243] [Cited by in F6Publishing: 283] [Article Influence: 243.0] [Reference Citation Analysis]
85 Temirbulatov II, Kryukov AV, Sychev DA. Pharmacogenetics of antiviral agents for the treatment of COVID-19. Fgen_Fgenom 2022. [DOI: 10.37489/2588-0527-2021-1-38-41] [Reference Citation Analysis]
86 Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, Malabade R, Gogtay J. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis 2022;22:1. [PMID: 34983406 DOI: 10.1186/s12879-021-07004-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
87 Kherabi Y, Lescure F, Yazdanpanah Y, Peiffer-smadja N. COVID-19 : les thérapeutiques. M�decine et Maladies Infectieuses Formation 2022. [DOI: 10.1016/j.mmifmc.2021.11.005] [Reference Citation Analysis]
88 Williamson BN, Pérez-pérez L, Schwarz B, Feldmann F, Holbrook MG, Singh M, Lye DS, Babusis D, Subramanian R, Haddock E, Okumura A, Hanley PW, Lovaglio J, Bosio CM, Porter DP, Cihlar T, Mackman RL, Saturday G, de Wit E. Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Karolyi M, Kaltenegger L, Pawelka E, Kuran A, Platzer M, Totschnig D, Koenig F, Hoepler W, Laferl H, Omid S, Seitz T, Traugott M, Arthofer S, Erlbeck L, Jaeger S, Kettenbach A, Assinger A, Wenisch C, Zoufaly A. Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients : A propensity score matched analysis. Wien Klin Wochenschr 2022;:1-9. [PMID: 36301355 DOI: 10.1007/s00508-022-02098-9] [Reference Citation Analysis]
90 Rumpf B, Lickefett B, Baumgartner C, Kauer V, Karolyi M, Pawelka E, Seitz T, Traugott M, Triska P, Bergthaler A, Laferl H, Wenisch C, Zoufaly A. Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants. Wien Klin Wochenschr 2022;:1-6. [PMID: 36070027 DOI: 10.1007/s00508-022-02084-1] [Reference Citation Analysis]
91 Bae EY, Sanders JM, Johns ML, Lin K, Ortwine JK, Wei W, Mang NS, Cutrell JB. Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now? Curr Infect Dis Rep 2021;23:28. [PMID: 34924819 DOI: 10.1007/s11908-021-00769-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Kojima Y, Nakakubo S, Kamada K, Yamashita Y, Takei N, Nakamura J, Matsumoto M, Horii H, Sato K, Shima H, Suzuki M, Konno S. Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study.. [DOI: 10.1101/2021.12.13.21267717] [Reference Citation Analysis]
93 Rao R, Musante CJ, Allen R. A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological Interventions.. [DOI: 10.1101/2021.12.07.21267277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Deplanque D, Cviklinski S, Bardou M, Ader F, Blanchard H, Barthélemy P, David I, D'Ortenzio E, Espérou H, Launay O, Lazarevic M, Lechat P, Lethiec F, Levy Y, Pérol D, Rage V, Roustit M, Thabut G. Crise sanitaire : quelles opportunités pour la recherche clinique sur le médicament ? Therapie 2021:S0040-5957(21)00254-7. [PMID: 34924206 DOI: 10.1016/j.therap.2021.11.010] [Reference Citation Analysis]
95 Khan N, Lamb L, Moores R. Clinical features and acute management of COVID-19 in adults. COVID-19 2021. [DOI: 10.1183/2312508x.10025520] [Reference Citation Analysis]
96 O'reilly S, Angeliadis M, Murtagh R, Gautier VW. Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. COVID-19 2021. [DOI: 10.1183/2312508x.10024020] [Reference Citation Analysis]
97 Núñez I, Soto-mota A. Assessing the evidence on remdesivir. The Lancet Infectious Diseases 2021;21:1630. [DOI: 10.1016/s1473-3099(21)00693-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Toroghi N, Abbasian L, Nourian A, Davoudi-Monfared E, Khalili H, Hasannezhad M, Ghiasvand F, Jafari S, Emadi-Kouchak H, Yekaninejad MS. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacol Rep 2021. [PMID: 34837648 DOI: 10.1007/s43440-021-00341-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
99 Jeck J, Jakobs F, Kron A, Cornely OA, Kron F. Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city. J Antimicrob Chemother 2021:dkab432. [PMID: 34849943 DOI: 10.1093/jac/dkab432] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva J, Poissy J, Peiffer-smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-duchamp M, the DisCoVeRy study group. Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial.. [DOI: 10.1101/2021.10.19.21265209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]